Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment

Koca, Gökhan; Yalnız-Akkaya, Züleyha; Gültekin, Sevinç; Yumuşak, Nihat; Demirel, Koray; Korkmaz, Meliha; Atilgan, Hasan Ikbal; Altiparmak, Uğur; Önal, Binnur; Örnek, Firdevs

doi:10.1016/j.remn.2013.01.006

Cited by 14 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the basis of the findings reported in the literature about the increase of oxidative stress during exposure to IR, the radioprotective ability of MLK also has been investigated. Koca et al [ 19,63 ] reported the efficacy of MLK against 131 I‐induced salivary and lacrimal glands damage in rats by gamma scintigraphy and demonstrated its potential protective role against 131 I‐induced damage in salivary glands. In another study, Tokat et al [ 64 ] investigated the radioprotective effects of MLK against 131 I‐induced pulmonary damage during radioiodine (RAI) therapy in differentiated thyroid carcinoma via histological examination.…”

Section: Discussionmentioning

confidence: 99%

“…[16][17][18] It is necessary to mention that the investigation of FDA-approved drugs with potential protective effect (compounds with antioxidant and anti-inflammatory properties) has especial popularity for developing radioprotective agent due to the certain toxicity and defined pharmacokinetics. [19][20][21][22][23] In the previous decade, scientists have paid more attention to these drugs, and some of these agents are still in preclinical or clinical stage. [24,25] Montelukast (MLK) is an FDA-approved drug that have been developed for respiratory dysfunction.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice

Hormati

Ardekani

Khodadust

et al. 2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Purpose In this study, we evaluated the renal protective effects of montelukast (MLK) against ionizing radiation (IR) induced nephrotoxicity in mice. Materials and Methods Radioprotective effects of MLK were assessed by biochemical analysis including measurements of kidney malondialdehyde (MDA), reduced glutathione (GSH), and serum creatinine and urea levels. Besides, for further evaluation of protective effects of MLK on renal system, 99mTc‐dimercaptosuccinic acid (DMSA) has been applied. The total antioxidant capacity of MLK was measured by using 1,1‐diphenyl‐2‐picryl hydrazyl radical reagents and compared with butylated hydroxyl toluene standard antioxidant. Results The biochemical evaluation revealed that better results have been achieved for the groups administered with MLK than the only radiation group. Besides only IR‐treated mice group, those treated with MLK demonstrated a significant decrease in urea and creatinine levels. Statistically, significant differences of MDA and SHG levels (P < .05) were found between the radiation group and MLK plus IR‐treated group. Also, 99mTc‐DMSA kidney uptake value (%ID/g) was observed lower for MLK plus IR‐treated mice group than only radiation‐treated mice group. Conclusions According to our findings, MLK has a potential role to be used as a renal protective agent against gamma radiation in radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice

Hormati

Ardekani

Khodadust

et al. 2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…However, these findings demonstrate the importance of alerting health professionals and patients to the possibility of occurrence of these events for early diagnosis and treatment. Although there is no effective method to prevent the adverse effects of radioiodine therapy on the lacrimal system, the use of antioxidants, such as vitamin E, lycopene, and montelukast, or NIS blockers, such as perchlorate, are potential therapeutic options.…”

Section: Discussionmentioning

confidence: 99%

Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In this study, the plasma cells were significantly lower in the ML group than in the RAI group in the liver tissue, while the groups were similar regarding the polymorphonuclear cells and lymphocytes in liver. Koca et al used ML for the protection of lacrimal (17) and salivary glands (16) from radiation damage. In both studies ML was found to be effective against radiation damage.…”

Section: Discussionmentioning

confidence: 99%

“…ML probably prevents inflammation by blocking the cysteinyl leukotriene receptor type 1, which is found in neutrophils. ML has been shown to down-regulate the human monocyte chemotaxins and to inhibit production of tumor necrosis factor-alpha (TNF-α) and monocytechemotactic protein-1 (17,31). In another study, it has been reported that ML depressed the TNF-α response in sepsis-induced ileal and hepatic injury in rats (17,27).…”

Section: Introductionmentioning

confidence: 99%

Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: A histopathological investigation in the rat model

Atilgan¹,

Yumuşak²,

Sadic³

et al. 2015

Ankara Üniversitesi Veteriner Fakültesi Dergisi

View full text Add to dashboard Cite

Summary: Radioactive iodine (131 I) is a known radionuclide which is used both for diagnostic and therapeutic purposes in the treatment of hyperthyroidism and thyroid cancer. Montelukast sodium (Cysteinyl leukotriene receptor-1 antagonist) is also a wellknown antioxidant drug. This study aimed to evaluate the histopathological changes in rat livers at the third month following 131 I treatment and the radioprotective effect of Montelukast sodium (ML) against 131 I-related liver damage. Thirty female Wistar Albino rats were randomly divided into three groups as control group (n=10), untreated rats; second (RAI) group (n=10), oral radioiodine (111 MBq) administrated rats, and third (ML) group (n=10), oral radioiodine and ML administrated rats. In the third group, ML administration was started 3 days before and ended 10 days after RAI administration. In the third month of radioiodine (RAI) administration, the animals were decapitated and the livers were removed for histopathological examination. The histopathologic data were evaluated comparatively by using Mann Whitney U and Fisher's Exact Tests Differences were determined in all the parameters in terms of intensity between the control and 131 I groups, which showed the harmful effects of 131 I. In the comparison of the 131 I and ML groups, hyperemia was determined respectively 80% to 40%, the presence of inflammatory cells 70% to 60% and capsule thickening 70% to 40%. Montelukast sodium was observed to have a protective effect especially on hyperemia and capsule thickening. According to the study results, radioactive iodine ( 131 I) treatment seems to cause morphological damage to the rat liver, and Montelukast sodium effectively protects the liver against damage.Key words: Iodine-131, histopathology, liver, montelukast sodium, rat. Karaciğerde radyoiodin ( 131 İ) toksisitesine karşı montelukast sodyumun radyoprotektif etkisi: Rat modelinde histopatolojik incelemelerÖzet: Radyoaktif iyot ( 131 I) hipertiroidizm ve tiroid kanserlerinin tanı ve tedavisi amacıyla kullanılan bir radyonükliddir. Montelukast sodyum (Cysteinyl leukotriene receptor-1 inhibitörü) ise antioksidan olarak bilinen bir ilaçtır. Bu çalışma ile rat karaciğerinde radyoiodinden (RAI) kaynaklanan radyasyon hasarına karşı Montelukast sodyumun (ML) radyoprotektif etkisinin histopatolojik olarak değerlendirilmesi amaçlandı. Çalışmada 30 adet dişi Wistar Albino rat kullanıldı ve bunlar rastgele üç gruba ayrıldı; birinci grubu hiçbir işleme tabi tutulmayan kontrol grubu (n=10), ikinci (RAI) grubu, (n=10), oral olarak RAI (111 MBq) uygulanan ratlar, üçüncü (ML) grubunu ise (n=10) oral olarak RAI ve ML uygulanan grup oluşturdu. Üçüncü çalışma grubunda ML uygulaması RAI uygulamasından 3 gün önce başlatıldı ve 10 gün sonra bitirildi. Üçüncü ay sonunda nekropsileri yapılan ratların karaciğer doku örnekleri rutin doku takibine alınarak histopatolojik olarak incelendi. Radyoiodin ve ML grubunda tüm histopatolojik bulgular Mann Whitney U testi ve Fisher'in ekzak test ile karşılaştırılarak değerlendirildi. Bütün ...

show abstract

Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment

Cited by 14 publications

References 23 publications

Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice

Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice

Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study

Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: A histopathological investigation in the rat model

Contact Info

Product

Resources

About